

Hodgkin Lymphoma Pathways

Patient Name: _____ Date of Birth: _____
Member Number: _____ Treatment Start Date: _____
Pathology: _____ Stage: _____
Line of Therapy: __1st Line __2nd Line __3rd Line __3rd Line+ ECOG Performance Status: _____ ICD-10 Code: _____
Biomarkers/Characteristics: (select all that apply)
CD20 status: __Negative __Positive HIV associated lymphoma: __No __Yes Transplant Candidate: __No __Yes

Classical Hodgkin Lymphoma | Early Stage (Stage I-IIA, Favorable and Unfavorable Risk)

___**ABVD**: doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT*

Classical Hodgkin Lymphoma | Advanced Stage (Stage IIB, III, and IV) | First Line of Therapy (1st Line)

___**ABVD**: doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (DTIC) ± ISRT*

___**A-AVD**: brentuximab vedotin, doxorubicin (Adriamycin), vinblastine, and dacarbazine†

*ISRT – Involved site radiation therapy

† Limited to Stage III and Stage IV

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.

